ARTICLE | Clinical News
INS365 ophthalmic solution: Began Phase II trial
January 10, 2000 8:00 AM UTC
Inspire Pharmaceuticals Inc., Durham, N.C. Product: INS365 ophthalmic solution Business: Ophthalmic Therapeutic category: Receptor agonist Target: P2Y2 receptors Description: P2Y2 receptor agonist In...